

REMARKS


The brief description of the drawings has been rewritten in this amendment to add FIGS. 2-3 to the description, and to more clearly associate SEQ. ID NOS. 1 and 2 with their meanings. The description was correspondingly amended to accurately reference the drawings.

Every line of the figures, except for the last line, corresponds to 60 nucleotides for a total of 2100 nucleotides. The last line of the figures corresponds to 23 more nucleotides making for a final total of 2123 nucleotides. FIG. 1 covers the first 780 nucleotides. FIG. 2 covers the next 780 nucleotides (781 – 1560). FIG. 3 covers the remaining 563 nucleotides for a grand total of 2123 nucleotides in all three figures combined. The top half of each line corresponds to SEQ. NO. 1, the nucleic acid sequence of the gene, while the bottom half of each line corresponds to SEQ. NO. 2, the protein translated from the coding sequence of SEQ. No. 1.

The amendment submitted herein is in reply to an Office of Patent Publication/Publishing Division Official Action. The amendment is needed to properly disclose the figures in the case. No new matter has been entered. The scope of the claims has not been affected. The review and entry of the amendment will require no substantial amount of additional work on the part of the office. Accordingly, entry of the amendment is respectfully requested.

Applicants believe all outstanding matters to be resolved. Applicants believe that no extension of term or other fees are required. If, however, any extension or fee is required, please charge Account No. 07-1250.

Respectfully,



Allan N. Kutzenko, Reg. 38,945
Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404

PH: (650) 522-6101

FX: (650) 522-5575

Date: 3/12/06